Explore our testing and therapeutics pipelines
Trial: PEAR-TNBC 
Location: United Kingdom 
Type: Observational Background
Triple negative breast cancer (TNBC) is a type of breast cancer that lacks receptors for estrogen and progesterone hormones and the HER2 protein. To treat TNBC, combination chemotherapies/immunotherapies are required. This is administered prior to surgery (known as neoadjuvant therapy).
Approximately 50% of patients with TNBC who receive neoadjuvant therapy achieve pathological complete response at surgery (pCR). This means that there is no sign or evidence of cancer in the breast tissue removed during surgery. There is a strong link between achieving pCR at surgery and long-term survival. It is therefore important to develop new treatment strategies that can improve pCR in patients with TNBC.
Description
This observational study is recruiting up to 60 patients with early TNBC that are eligible for neoadjuvant therapy followed by surgery. Patients are expected to attend an additional procedure to remove a small piece of tumor using a core needle biopsy. This tumor will be used for analysis on Pear Bio’s system to determine the likelihood of response to a given neoadjuvant therapy regimen. As this is an observational study, the results will not be shared with the treating oncologist at the time of initial treatment, and you will be treated using the standard of care. The goal of the study is to establish the accuracy of Pear’s test at predicting pathological complete response to help guide future patients to better treatments for their cancer.
If you are interested in enrolling, please contact your doctor about whether you are eligible. For more information, contact trials@pearbio.com
Open Sites and Investigators
Trial: PEAR-MET Location: United Kingdom Type: Observational Background
Triple negative breast cancer (TNBC) is a type of breast cancer that lacks receptors for estrogen and progesterone hormones and the HER2 protein. Once the disease has spread (metastasized), it is generally treated with a range of systemic therapies, such as chemotherapy, targeted therapy and immunotherapy. Different patients may respond to different treatments, but at the moment, there is no way of predicting who will respond to which drugs.
Description
This observational study is recruiting up to 30 patients with metastatic or locally advanced TNBC that are due to start a new line of treatment. Patients will need to undergo an additional procedure to remove a small piece of tumor using a core needle biopsy. This tumor will be used for analysis on Pear Bio’s system to determine the likelihood of response to a given treatment regimen. As this is an observational study, the results will not be shared with the treating oncologist at the time of initial treatment, and you will be treated using the standard of care. The goal of the study is to establish the accuracy of Pear’s test at predicting response to treatment to help guide future patients to better treatments for their cancer.
If you are interested in enrolling, please contact your doctor about whether you are eligible. For more information, contact trials@pearbio.com
Open Sites and Investigators
Trial: PEAR-TREE 2 Location: United Kingdom, United States Type: Observational Background
Kidney cancer is an area of high unmet need. At the moment, advanced or metastatic cancer is often treated with a combination of drugs, including immunotherapy and targeted drugs. Although there are a number of different drugs and combination therapies that can be used, there is no way of predicting who will respond to which drugs. Some patients receive drugs that they don’t respond to.
Description
This observational study is recruiting up to 200 patients with advanced or metastatic kidney cancer who are due to start new treatment with immunotherapy or targeted drugs. Patients are expected to attend an additional procedure to remove a small piece of tumour using a core needle biopsy. This tumour will be used for analysis on Pear’s system to determine the likelihood of response to a given treatment regimen. As this is an observational study, the results will not be shared with your oncologist at the time of initial treatment, and you will be treated using the standard of care. The goal of the study is to establish the accuracy of Pear’s test at predicting disease response to help guide future patients to better treatments.
If you are interested in enrolling, please contact your doctor about whether you are eligible. For more information, contact trials@pearbio.com
Open Sites and Investigators
Trial: PEAR-GLIO Location: United Kingdom Type: Observational Background
Brain tumours are the leading cause of cancer death in the under-40s, and are one of the least researched cancers.
Although there are a number of different drugs, and combinations of drugs, which can be used, we have no way of predicting who will respond to which drugs. This means that some people receive drugs that they don’t respond to.
Description
This observational study is recruiting up to 50 patients with primary brain tumors who are undergoing surgery. Patients will have surgery as planned, and donate a 40ml blood sample. We will use excess tissue from the operation (which would otherwise go to waste), along with the blood sample, to explore the effect of different drugs on the tumor. This tumor will be used for analysis on Pear Bio’s system to determine the likelihood of response to a given treatment regimen. As this is an observational study, the results will not be shared with the treating oncologist at the time of initial treatment, and you will be treated using the standard of care. The goal of the study is to establish the accuracy of Pear’s test at predicting response to treatment to help guide future patients to better treatments for their cancer.
If you are interested in enrolling, please contact your doctor about whether you are eligible.
For more information, contact trials@pearbio.com
Open Sites and Investigators
Mechanism of Action
Cyclin-dependent kinases (CDKs) play a critical role in the cell cycle, and are often overactive in cancer, leading to high cell proliferation. CDK12 plays a critical role in transcription (G1 to S phase of cell cycle). By inhibiting CDK12 activity to stop hyper-transcription in cancer, cell proliferation is reduced, with eventual cancer cell death.
Differentiated Data
1. Pear Bio’s molecules have low nanomolar potencies at high ATP concentrations.
2. Our lead series demonstrates improved safety compared to existing molecules, addressing common
ADMET issues like hERG (heart) toxicity and high liver clearance.
3. Pear Bio molecules have demonstrated high efficacy in HER2 low breast cancer organoids.
Mechanism of Action
VSIG4 is an immuno-suppressive receptor found on tumor-associated macrophages (TAMs). VSIG4 inhibits effector T cells directly, and also contributes to cold, pro-tumor microenvironments through the cytokines released by TAMs. Antibodies that block VSIG4 are able to prevent T cell suppression and repolarize TAMs to a pro-inflammatory phenotype to drive anti-tumor immune responses.
Differentiated Data
1. Multiple hit antibodies have demonstrated >100x KD improvement compared to known antibodies.
2. Antibody series hits a diverse set of different domains and epitopes of VSIG4.
See how our personalized testing works
